Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INS19
- Development stage
- Phase 1
- Lead developer
- Insmed
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
INS19 is a follow-on biologic version of filgrastim (Neupogen), a recombinant human granulocyte colony-stimulating factor (G-CSF) developed by Insmed to prevent infections in cancer patients undergoing chemotherapy. It demonstrated bioequivalence to Neupogen in early clinical studies and was planned for Phase III evaluation before Insmed sold its follow-on biologics program, including INS19, to Merck in 2009 for $130 million. Separately, a distinct investigational CAR-T cell therapy named INS19 CAR-T Cells, targeting CD19, is under development by Beijing Imunopharm Technology for relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in a Phase 1 trial (NCT06209671).
- Other names
- INS19 CAR-T CellsINS-19 CAR-T CellsINS 19 CAR-T Cells
02
Targets
CD19 (B lymphocyte antigen CD19)CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on INS19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INS19.